Category: 946426-89-7

Synthetic Route of 946426-89-7, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.946426-89-7, Name is 5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-methanol, molecular formula is C13H11Cl2NO2. In a Patent£¬once mentioned of 946426-89-7

A spiro compound and its pharmaceutical use (by machine translation)

The invention relates to a FXR receptor agonists as a spiro compound, the chemical structure shown in formula I, its pharmaceutically acceptable salt, or their enantiomers, diastereoisomers, tautomers, racemate, solvate, N – oxide or amino acid conjugate and its pharmaceutical composition, and in the preparation of the treatment of FXR receptor mediated diseases in use. (by machine translation)

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 946426-89-7

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Application of 946426-89-7, The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.946426-89-7, Name is 5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-methanol, molecular formula is C13H11Cl2NO2. In a Patent£¬once mentioned of 946426-89-7

Novel FXR (NR1H4) binding and activity modulating compounds

The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of the NR1H4 receptor (FXR). The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds. wherein R is selected from the group consisting of COOR6, CONR7R8, tetrazolyl, SO2NR7R8, C1-6 alkyl, SO2-C1-6 alkyl and H, with R6 independently selected from the group consisting of H or C1-6 alkyl, and R7 and R8 independently from each other selected from the group consisting of H, C1-6 alkyl, halo-C1-6 alkyl, C1-6 alkylene-R9, SO2-C1-6 alkyl, wherein R9 is selected from the group consisting of COOH, OH and SO3H; A is selected from the group consisting of phenyl, pyridyl,pyrimidyl, pyrazolyl, indolyl, thienyl, benzothienyl, indazolyl, benzisoxazolyl, benzofuranyl, benzotriazolyl, furanyl, benzothiazolyl, thiazolyl, oxadiazolyl, each optionally substituted with one or two groups independently selected from the group consisting of OH, O-C1-6 alkyl, O-halo-C1-6 alkyl, C1-6 alkyl, halo-C1-6 alkyl, C3-6 cycloalkyl and halogen; Q is selected from the group consisting of phenyl, pyridyl, thiazolyl, thiophenyl, pyrimidyl, each optionally substituted with one or two groups independently selected from the group consisting of C1-6 alkyl, halo-C1-6 alkyl, halogen and CF3;Y is selected from N or CH; Z is selected from wherein X= CH, N, NO.

A reaction mechanism is the microscopic path by which reactants are transformed into products. Each step is an elementary reaction. In my other articles, you can also check out more blogs about 946426-89-7

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Related Products of 946426-89-7, A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 946426-89-7, Name is 5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-methanol, molecular formula is C13H11Cl2NO2. In a Patent£¬once mentioned of 946426-89-7

FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF

The present disclosure disclosed a modulator of FXR receptor and preparation and use thereof, which relates to the technical filed of medicinal chemistry. The present disclosure provides a modulator of FXR receptor having a structural formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, which can combine with FXR receptor (that is NR1H4) and be acted as a FXR agonist or a partial agonist for preventing and treating the disease mediated by FXR, such as chronic intrahepatic or extrahepatic cholestasis, hepatic fibrosis caused by chronic cholestasis or acute intrahepatic cholestasis, chronic hepatitis B, gallstone, hepatic carcinoma, colon cancer or intestinal inflammatory disease, etc. Specifically, for some chemical compounds, their EC50 for FXR agonist activity reach below 100nM, which show an excellent FXR agonist activity and an excellent prospect to provide a new pharmaceutical selection in clinical treatment for the disease mediated by FXR.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Related Products of 946426-89-7. In my other articles, you can also check out more blogs about 946426-89-7

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

One of the major reasons for studying chemical kinetics is to use measurements of the macroscopic properties of a system, Product Details of 946426-89-7, such as the rate of change in the concentration of reactants or products with time.In a article, mentioned the application of 946426-89-7, Name is 5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-methanol, molecular formula is C13H11Cl2NO2

BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Sometimes chemists are able to propose two or more mechanisms that are consistent with the available data. Product Details of 946426-89-7, If a proposed mechanism predicts the wrong experimental rate law, however, the mechanism must be incorrect.Welcome to check out more blogs about 946426-89-7, in my other articles.

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 946426-89-7, name is 5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-methanol, introducing its new discovery. COA of Formula: C13H11Cl2NO2

Heterocyclic french Nepal ester derivatives X receptor modulators (by machine translation)

The invention relates to a heterocyclic compound and contains the same component composition preparation method and its as french Nepal ester X receptor (FXR) derivatives of the active use of the regulator, the regulator shown in formula I of the heterocyclic compound, or its pharmaceutically acceptable salt, prodrug, compound solvent, polymorphism body, isomer, and stable isotope derivatives. The invention relates to compounds can be used for the treatment or prevention of the diseases related to the FXR-mediated by, the related disease is due to the carbohydrate, lipid or bile metabolism caused by abnormal. (by machine translation)

We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 946426-89-7, and how the biochemistry of the body works.COA of Formula: C13H11Cl2NO2

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

946426-89-7, Name is 5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-methanol, belongs to Isoxazoles compound, is a common compound. COA of Formula: C13H11Cl2NO2In an article, once mentioned the new application about 946426-89-7.

ALKENE COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

The present invention provides compounds of Formula (I): Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds modulate the activity of famesoid X receptor (FXR), for example, as agonists. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Do you like my blog? If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 946426-89-7

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Electric Literature of 946426-89-7, Chemistry is the experimental science by definition. We want to make observations to prove hypothesis. For this purpose, we perform experiments in the lab. 946426-89-7, Name is 5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-methanol,introducing its new discovery.

ISOXAZOLYL-CARBONYLOXY AZABICYCLO[3.2.1]OCTANYL COMPOUNDS AS FXR ACTIVATORS

The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, L2, A, B, R1, R2, R3, and R4 are described herein.

We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 946426-89-7, and how the biochemistry of the body works.Electric Literature of 946426-89-7

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

Related Products of 946426-89-7, A catalyst don’t appear in the overall stoichiometry of the reaction it catalyzes, but it must appear in at least one of the elementary reactions in the mechanism for the catalyzed reaction. 946426-89-7, Name is 5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-methanol, molecular formula is C13H11Cl2NO2. In a Patent£¬once mentioned of 946426-89-7

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

Balanced chemical reaction does not necessarily reveal either the individual elementary reactions by which a reaction occurs or its rate law.Related Products of 946426-89-7. In my other articles, you can also check out more blogs about 946426-89-7

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 946426-89-7, name is 5-Cyclopropyl-3-(2,6-dichlorophenyl)isoxazole-4-methanol, introducing its new discovery. 946426-89-7

COMPOUNDS USEFUL IN MODULATING THE FARNESOID X RECEPTOR AND METHODS OF MAKING AND USING THE SAME

Provided are compounds that can act as a modulator of a farnesoid X receptor (FXR) and that can be useful in the treatment of diseases and/or disorders associated with the FXR. Compositions including such compounds are also provided along with methods for preparing compounds of the present invention and their use.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.946426-89-7, you can also check out more blogs about946426-89-7

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem

946426-89-7, Catalysts function by providing an alternate reaction mechanism that has a lower activation energy than would be found in the absence of the catalyst. In a patent, 946426-89-7, molecular formula is C13H11Cl2NO2, introducing its new discovery.

NOVEL FXR (NR1H4) MODULATING COMPOUNDS

The present invention relates to compounds which bind to the NR1 H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.946426-89-7, you can also check out more blogs about946426-89-7

Reference£º
Isoxazole – Wikipedia,
Isoxazole | C3H3NO – PubChem